Acadia Pharmaceuticals | ACAD - Assets


Acadia Pharmaceuticals reported $1.33B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
ALKERMES USD 2.33B 76.7M Sep/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Cara Therapeutics USD 43.75M 4.8M Jun/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
Eisai JPY 1.49T 48.22B Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Moderna USD 12.34B 203M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Prothena USD 352.63M 46.44M Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025